

The immune response

The immune system comprises **two arms** functioning cooperatively to provide a comprehensive protective response: the **innate** and the **adaptive immune systems**.

The **innate immune system** is primitive, does not require the presentation of an antigen (Ag) and does not lead to immunological memory.

Its effector cells are **neutrophils**, **macrophages** and **mast cells**, reacting within minutes to hours with the help of complement activation and cytokines (CKs).






Fig. 1.1

B and T lymphocytes

B lymphocytes



T lymphocytes



MHC, major histocompatibility complex.

Fig. 1.2

Lymphocytes develop in **primary lymphoid tissue** (bone marrow [BM], thymus) and circulate towards secondary lymphoid tissue (lymph nodes [LNs], spleen, mucosa-associated lymphoid tissue [MALT]).

The Ag **reaches the LN** carried by lymphocytes or dendritic cells. Lymphocytes enter the LN from blood transiting through specialised endothelial cells.

The Ag is **processed** within the LN by lymphocytes, macrophages and other immune cells in order to mount a specific immune response.

The **adaptive immune response** is provided by the **lymphocytes**, which precisely recognise unique Ags through cell-surface receptors.

Receptors are produced in billions of variations through cut and splicing of genes and subsequent negative selection: thus, self-recognising lymphocytes are eradicated.

Immunological memory after an Ag encounter permits a faster and heightened state of response on a subsequent exposure.

Primary and secondary lymphoid tissues




Fig. 1.3

REVISION QUESTIONS


1. What are the effector cells of the innate immune system?
2. Which cells are responsible for immune memory?
3. In which anatomical structure are the Ags processed by lymphocytes?

Immunoglobulins (Igs) and B-cell development


The final task of the lymphocytes (B cells) developed in the BM is the production of Ag-specific Igs, which function as **antibodies (Abs)**.

Ig's are proteins secreted by or present on the surface of B cells, assembled from identical pairs of heavy (H) and light (L) chains.

The highly variable N-terminal regions are the fragment antigen-binding (**Fab**) portion. The constant domains interact with the fragment crystallisable (**Fc**) **receptors** on the effector cells.



Ag, antigen; CDR, complementary-determining region; Fab, fragment antigen-binding; Fc, fragment crystallisable.



Ig, immunoglobulin.

There are five classes of Igs: M, G, A, E and D, distinguished by different H chains. B cells can change the class of Ig produced: **class switching**.


Before being capable of producing Ag-specific Ig, B cells must undergo a number of **transformations**, first in the BM and subsequently in the LNs.

In the rest of the cells in the body (not B cells), the genes encoding the H and L chains of the Ig are distributed in many segments, thus **they cannot be expressed**.

These gene segments **must be rearranged** within the chromosome in the B cells so the final gene structure allows the expression of a functional protein.

The first stages of B-cell development occur in the BM, where pro-B cells first **rearrange** the Ig **H chain gene** to become pre-B cells.

Pre-B cells continue this **somatic recombination** process by rearranging the **L chain** to become immature B cells, expressing IgM on their surface.



D, diversity; H, heavy; L, light; J, joining; Rag, recombinaise activating gene; V, variable.

REVISION QUESTIONS


1. What are the Fab and the Fc portions of an Ig?
2. What distinguishes a pre-B from a pro-B from an immature B cell?
3. What is meant by the term 'somatic recombination'?

B-cell diversity

In B cells, the variable regions of the Ig L chains are encoded by the random joining of one of many **variable (V)** and **joining (J)** segment genes.

In addition to the above, for the H chain gene, a **diversity (D)** gene must also be rearranged.

The result of this random process is the expression on any individual naïve B-cell surface of a **unique Ig** with Ag specificity: the **B-cell receptor (BCR)**.



VDJ, variability, diversity and joining.

Germinal centre





Fig. 1.8

In the peripheral dark zone of the GC, rapidly dividing B cells (centroblasts [CBs]) introduce random mutations in the H and L chains (**somatic hypermutation**).

In the central light zone, CBs mature to centrocytes (CCs) and are **selected for affinity** with the help of T-follicular helper cells and dendritic cells.

High-affinity CCs mature to either plasma cells or memory B cells and **leave the GC**. They may undergo Ig class switching by changing the Ig H chain.



CSR, class-switch recombination; FDC, follicular dendritic cell; SHM, somatic hypermutation.

REVISION QUESTIONS

1. What are the phases of B-cell development and where do they take place?
2. How is the diversity of Ig specificity derived?
3. What is meant by 'somatic hypermutation'?

T cells and natural killer (NK) cells

T lymphocytes arise in the BM but soon migrate to the thymus, where they mature to express the Ag-binding **T-cell receptor (TCR)** on their membrane.

The TCR is a dimer composed of two chains, usually α and β . Similar to the BCR, each one of these chains includes a **variable** and a **constant domain**.

T cells are able to recognise Ags (through their TCR) only when the Ag is bound to a **major histocompatibility complex (MHC)** molecule.

T-cell receptor structure




Fig. 1.10

T-cell maturation




Fig. 1.11

MHC, major histocompatibility complex; TCR, T-cell receptor.

Activated **Th cells** divide and produce a clone of effector cells, which in turn secrete CKs, activating other components of the immune response.

Once activated, **Tc cells** induce apoptosis of dysfunctional cells (i.e. infected) by enzymatic or signalling processes. NK cells have a similar function.

Memory T cells are produced after Ag exposure. They remain quiescent and provide an enhanced response after repeated exposure to the Ags.

After migrating to the secondary lymphoid organs, naïve T cells are exposed to Ags which bind to the TCR. **TCR activation** induces proliferation and differentiation.

T cells mature to distinct **T-helper (Th)** and **T-cytotoxic (Tc)** populations characterised by expression of CD4 and CD8, respectively.

There are two classes of MHC molecules: **class I** and **class II**. Th cells recognise Ags in the context of class II MHC, whereas Tc cells recognise Ags bound to class I MHC.

Natural killer cell activation




Fig. 1.12

MHC, major histocompatibility complex; NK, natural killer.

REVISION QUESTIONS

1. What is the structure of the TCR?
2. How can Th and Tc cells be easily distinguished from one another?
3. What is the main function of Tc cells?

Immune system activity

CKs are low molecular weight proteins that play a key role in the induction and regulation of the immune response.

Produced by a variety of cells, their actions are mediated through their receptive receptors; they exert **autocrine**, **paracrine** and **endocrine** effects.

CKs regulate the **intensity** and **duration** of both the innate and adaptive immune response.

Cytokines




Fig. 1.13

APC, antigen-presenting cell; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFN, interferon; IL, interleukin; LAK, lymphokine-activated killer; M-CSF, macrophage colony-stimulating factor; MHC, major histocompatibility complex; NK, natural killer; Tc, T cytotoxic; TCR, T-cell receptor; TGF, transforming growth factor; TNF, tumour necrosis factor.

Antigen processing and presentation




Fig. 1.14

This way APCs carry **cargos of foreign Ags** to lymphoid organs, where they are recognised by Th cells that initiate the adaptive response.

All aspects of the adaptive response are initiated and **controlled** by T cells. They recruit immunological effector mechanisms by direct contact or through CKs.

Abs may cause direct cytotoxicity by activation of the complement cascade or by recruiting effector cells (NK, macrophages, etc.) that cause cell death.

Antibody-mediated cytotoxicity




Fig. 1.15

REVISION QUESTIONS

1. What are CKs and how do they exert their function?
2. What is the role of APCs?
3. Which mechanisms are employed by Abs to cause dysfunctional cell death?

Summary: The immune system

- Cells of the primitive innate immune system and the Ag-specific adaptive immune system act as a cooperative network to bring about a coordinated and tightly regulated immune response to foreign Ags
- The primitive innate immune system uses a limited pattern of recognition molecules and, although it retains no memory, is able to mount a rapid response
- The Ag-specific adaptive immune system recognises a huge diversity of different specific Ags and elicits a response that is highly specific and retains memory
- Diversity and Ag specificity in both the TCR and BCR result from somatic recombination and the random splicing of a selected number of gene segments
- When naïve B cells encounter an Ag, further Ag specificity is added by somatic hypermutation in the GC of secondary lymphoid organs
- Only the most avid Ag-binding cells mature to become either Ab-producing plasma cells or memory B cells
- Abs may switch to different classes with differing effector functions and tissue locations while retaining the same Ag specificity in their variable regions
- In response to Ags, T cells differentiate to effector T cells that may augment the immune response, cytotoxic T cells that destroy altered self-cells, or regulatory T cells
- CKs regulate the immune response by autocrine, paracrine and endocrine mechanisms
- Cooperative interactions of both facets of the immune response result in efficient effector mechanisms that clear foreign Ags with residual immunological memory

Further Reading

Fugmann SD, Lee AI, Shockett PE, et al. The RAG proteins and V(D)J recombination: complexes, ends, and transposition. *Annu Rev Immunol* 2000; 18:495–527.

Helbert M. *Flesh and Bones of Immunology*. Edinburgh: Mosby Ltd., Elsevier, 2006.

Jaffe ES, Harris NL, Stein H, et al. Introduction and overview of the classification of lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al (Eds). *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, 4th edition. Lyon: International Agency for Research on Cancer, 2008; 158–166.

Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. *Nat Rev Immunol* 2008; 8:22–33.

Kracker S, Durandy A. Insights into the B cell specific process of immunoglobulin class switch recombination. *Immunol Lett* 2011; 138:97–103.

Mucinda D, Cheroutre H. The many face-lifts of CD4 T helper cells. *Adv Immunol* 2010; 107:139–152.

Parham P. *The Immune System*, 5th edition. New York: W. W. Norton & Company, 2021.

Punt J, Stranford S, Jones P, Owen JA. *Kuby Immunology*, 8th edition. New York: W. H. Freeman, 2018.

Rathmell JC, Thompson CB. The central effectors of cell death in the immune system. *Annu Rev Immunol* 1999; 17:781–828.

Sun JC, Lanier LL. NK cell development, homeostasis and function: parallels with CD8⁺ T cells. *Nat Rev Immunol* 2011; 11:645–657.

Image sources: **Fig. 1.1.** Dranoff G. *Nat Rev Cancer* 2004;4:11-22; **1.2.** Kaiser G. *Microbiology* ([https://bio.libretexts.org/Bookshelves/Microbiology/Microbiology_\(Kaiser\)](https://bio.libretexts.org/Bookshelves/Microbiology/Microbiology_(Kaiser))); **1.4.** Fix D, Professor at Southern Illinois University (<https://myplace.frontier.com/~dffix/medmicro/igs.htm>); **1.7.** http://www.talkdesign.org/faqs/Evolving_Immunity.html; **1.8.** Levy N, Dartmouth College; **1.9.** Klein U, Dalla-Favera R. *Nat Rev Immunol* 2008;8:22-33; **1.10.** Hunt R. www.microbiologybook.org; **1.11.** https://en.wikipedia.org/wiki/File:Antigen_presentation.jpg; **1.12.** French AR, Yokoyama WM. *Arthritis Res Ther* 2003;2004:6:8-14; **1.15.** Casadevall A, et al. *Nat Rev Microbiol* 2004;2:695-703.

Did you find this chapter useful?

Would you like to read more?

If you are an ESMO Member, simply log in to your account to download the complete book along with over 20 other titles on a broad range of topics - all of them written to assist you in your daily practice.

If not an ESMO Member, then consider joining!

ESMO Members belong to a global community of over 35,000 oncology professionals. Membership provides you many other benefits, including:

- **Full access to ESMO educational and scientific resources**, all centralised on our portal OncologyPRO
- An **online subscription to Annals of Oncology**
- A wide range of **exclusive courses and learning opportunities** for every stage of your career
- **Reduced registration fees** for ESMO meetings

[Discover more](#) and [join ESMO](#) today!